Therapie der hochaktiven Multiplen Sklerose

ZUSAMMENFASSUNG

Immuntherapien bei Multipler Sklerose müssen sich nach randomisiert kontrollierten klinischen Studien auch in der klinischen Routine bewähren. Dazu werden Register- und Kohortenstudien durchgeführt. Eine große Kohortenstudie an den Universitätskliniken Essen-Duisburg und Münster untersucht Wirksamkeit und Sicherheit von Cladribin-Tabletten im klinischen Alltag. Erste Analysen scheinen die Ergebnisse der Zulassungsstudie CLARITY in einer breiter gefassten Patientenpopulation zu bestätigen.

ABSTRACT

Immunotherapies for multiple sclerosis must also prove themselves in clinical routine after randomized controlled clinical trials. For this purpose, registry and cohort studies are carried out. A large cohort study at the university hospitals of Essen-Duisburg and Münster is investigating the efficacy and safety of cladribine tablets in everyday clinical practice. Initial analyses seem to confirm the results of the CLARITY registration study in a broader patient population

Schlüsselwörter

Hochaktive Multiple Sklerose - Kohortenstudie - Cladribin-Tabletten - Immunologie - Wirksamkeit - Sicherheit

Key words

Highly active multiple sclerosis - cohort study - cladribine tablets - immunology - efficacy - safety

• Literatur

• 1 Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011; 34: 28-35
• 2 Fachinformation Mavenclad ^® Stand: Juli 2018
• 3 Giovannoni G, Comi G, Cook S. et al A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426
• 4 Soelberg Sørensen P, Dangond F, Hicking C. et al Long-term lymphocyte counts in patients with relapsingremitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg: total lymphocytes, B and T cell subsets. Mult Scler 2017; 23 (Suppl. 03) 310 Abstract P566
• 5 Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol 2011; 7 (Suppl. 01) S1
• 6 Soelberg-Sørensen S, Comi G, Cook S. et al Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial. J Neurol 2009; 256 (Suppl. 02) S127-S128
• 7 PREMIERE-Register https://www.clinicaltrials.gov/ct2/show/NCT01013350?term=PREMIERE&cond=Multiple+Sclerosis&draw=2&rank=1 letzter Zugriff 30.10.2019
• 8 Cook S, Leist T, Comi G. et al Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord 2019; 29: 157-167
• 9 Cook S, Giovannoni G, Leist T. et al ECTRIMS. 2019 Poster P1390 https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/278591/s.cook.updated.safety.of.cladribine.tablets.in.the.treatment.of.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dp1390 letzter Zugriff 30.10.2019
• 10 Cohen JA, Coles AJ, Arnold DL. et al Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis. Lancet 2012; 380: 1819-1828
• 11 Kappos L, Radue EW, O’Connor P. et al A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401